LB P2L
Alternative Names: LB-P2LLatest Information Update: 28 Apr 2024
At a glance
- Originator LISCure Biosciences
- Developer LISCure Biosciences; The Scripps Research Institute
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Apr 2024 Preclinical trials in Solid tumours in South Korea (PO) before April 2024 (LISCure Biosciences pipeline, April 2024)